FDA Approves Upadacitinib for Giant Cell Arteritis in Adults Dr. Kamal Kant Kohli2 May 2025 5:30 AM ISTThe FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for...
USFDA approves AbbVie giant cell arteritis drug Rinvoq in adults Ruchika Sharma30 April 2025 4:30 PM ISTNorth Chicago, Ill.: AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib), 15 mg, once daily,...
FDA approves Upadacitinib for Crohn's disease in adults Dr. Kamal Kant Kohli19 May 2023 10:00 AM ISTThe U.S. Food and Drug Administration (FDA) has approved Upadacitinib for treatment of adults with moderately to severely active Crohn's disease...
AbbVie gets positive EMA committee opinion for Upadacitinib to treat adults with moderate to severe Crohn's disease Ruchika Sharma28 Feb 2023 1:30 PM ISTDiscovered and developed by AbbVie scientists, upadacitinib is a selective and reversible Janus Kinase (JAK) inhibitor.
AbbVie raises sales outlook of Skyrizi, Rinvoq to USD 17.5 billion in 2025 MD Bureau13 Jan 2023 2:26 PM ISTThe two drugs Skyrizi and Rinvoq are part of AbbVie's long term growth strategy to offset Humira's loss of exclusivity.
Abbvie RINVOQ gets European Commission nod for treatment of Active Non-Radiographic Axial Spondyloarthritis in adults Ruchika Sharma31 July 2022 11:30 AM ISTAbbvie RINVOQ gets European Commission nod for Adults with Active Non-Radiographic Axial Spondyloarthritis
CHMP Approves Upadacitinib for Treating Active Psoriatic Arthritis and Ankylosing Spondylitis Hina Zahid14 Dec 2020 12:08 PM ISTNORTH CHICAGO, Ill., - AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
Upadacitinib bests abracept in tough Rheumatoid Arthritis Cases: NEJM study Dr. Nandita Mohan22 Oct 2020 10:57 AM ISTUpadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid arthritis. The efficacy and safety of upadacitinib as compared with...
